Terminated PHASE2 INTERVENTIONAL 3-arm NCT01900795

An Analgesic Study to of V117957 for the Treatment of Postsurgical Pain Due to Third Molar Extraction

A Phase 2a, Single-Center, Randomized, Double-Blind, Double- Dummy, Placebo- and Active-Controlled Analgesic Study of an Oral Dose of V117957 4.5 mg for the Treatment of Postsurgical Pain Due to Third Molar Extraction

Sponsor: Purdue Pharma LP

Conditions Postsurgical Pain Due to Third Molar Extraction

Interventions Ibuprofen Placebo V117957

Updated 6 times since 2017 Last updated: Dec 3, 2013 Started: Jul 31, 2013 Primary completion: Nov 30, 2013 Completion: Nov 30, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Terminated early due to administrative reasons not related to safety.

Other terminated trials from Purdue Pharma LP

See all terminations from Purdue Pharma LP

A PHASE2 clinical study on Postsurgical Pain Due to Third Molar Extraction, this trial is terminated or withdrawn. The trial is conducted by Purdue Pharma LP and has accumulated 6 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Jul 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Purdue Pharma LP

Data source: Purdue Pharma LP

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Austin, United States